Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00193609 · ClinicalTrials.gov registry record · Phase 2
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
A Phase 2 study of Neoplasms, Unknown Primary, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 10
- Study locations
NCT00193609 is a Phase 2 study of Neoplasms, Unknown Primary that has completed, run by SCRI Development Innovations. The registered enrollment target is 48 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT00193609, a Phase 2 study of Neoplasms, Unknown Primary, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 10
- Study locations
Study Summary
In this phase II trial, we will evaluate the feasibility and efficacy of the oxaliplatin/capecitabine combination in patients who have had one previous chemotherapy regimen for the treatment of carcinoma of unknown primary site. Patients who are relapsed after a previous response to treatment will be eligible, as well as those who were refractory to first-line therapy.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Oxaliplatin
Study Locations (10)
Kentucky
- Greenview Regional Hospital - Bowling Green
- Consultants in Blood Disorders and Cancer - Louisville
Tennessee
- Chattanooga Oncology Hematology Associates - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Florida
- Integrated Community Oncology Network - Jacksonville
Indiana
- AP&S Oncology & Hematology Northside - Terre Haute
Louisiana
- Baton Rouge General Medical Center - Baton Rouge
Ohio
- Oncology Hematology Care - Cincinnati
Pennsylvania
- Reading Hospital Regional Cancer Center - West Reading
South Carolina
- Spartanburg Regional Medical Center - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00193609
The ClinicalTrials.gov registry entry for NCT00193609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms, Unknown Primary appearing as the primary indexed condition, and to 2 interventions - of which Capecitabine is the first listed.
NCT00193609 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Kentucky, Tennessee, Florida.
Frequently Asked Questions
What is clinical trial NCT00193609 about?
NCT00193609 is a clinical study titled "Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site". In this phase II trial, we will evaluate the feasibility and efficacy of the oxaliplatin/capecitabine combination in patients who have had one previous chemotherapy regimen for the treatment of carcinoma of unknown primary site. Patients who are relapsed after a previous response to treatment will b...
What is the current status of trial NCT00193609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2004-09. Estimated completion is 2009-01.
What conditions does trial NCT00193609 study?
This clinical trial studies the following conditions: Neoplasms, Unknown Primary.
What interventions are being tested in trial NCT00193609?
The interventions under investigation include: Capecitabine (DRUG), Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00193609?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00193609 being conducted?
This trial has 10 study locations across Florida, Indiana, Kentucky, Louisiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms, Unknown Primary
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.